Perrigo (PRGO) Given a $107.00 Price Target at Cantor Fitzgerald
Perrigo (NYSE:PRGO) has been given a $107.00 price objective by equities research analysts at Cantor Fitzgerald in a report released on Monday. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 28.02% from the company’s previous close.
Several other analysts have also issued reports on the stock. Deutsche Bank upped their price target on shares of Perrigo from $88.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, September 14th. Royal Bank Of Canada reaffirmed a “sell” rating and set a $64.00 price target on shares of Perrigo in a research report on Wednesday, September 13th. Canaccord Genuity reaffirmed a “buy” rating and set a $100.00 price target (up from $88.00) on shares of Perrigo in a research report on Wednesday, September 13th. Wells Fargo & Company upped their price target on shares of Perrigo to $90.00 and gave the stock a “market perform” rating in a research report on Friday, November 10th. Finally, Jefferies Group reaffirmed a “hold” rating and set a $81.00 price target on shares of Perrigo in a research report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company’s stock. Perrigo presently has a consensus rating of “Hold” and a consensus target price of $92.07.
Shares of Perrigo (NYSE:PRGO) traded down $2.72 on Monday, reaching $83.58. 1,341,482 shares of the company traded hands, compared to its average volume of 1,696,366. Perrigo has a fifty-two week low of $63.68 and a fifty-two week high of $91.73. The firm has a market capitalization of $12,150.00, a PE ratio of 17.75, a price-to-earnings-growth ratio of 1.85 and a beta of 0.64. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.72 and a quick ratio of 1.24.
In other Perrigo news, EVP Jeffrey Needham sold 3,595 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $89.49, for a total transaction of $321,716.55. Following the sale, the executive vice president now directly owns 10,118 shares in the company, valued at $905,459.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sharon Kochan sold 318 shares of the stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $81.36, for a total transaction of $25,872.48. Following the sale, the executive vice president now owns 10,231 shares in the company, valued at $832,394.16. The disclosure for this sale can be found here. Insiders sold 4,514 shares of company stock worth $400,009 over the last three months. Insiders own 6.90% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its stake in shares of Perrigo by 11.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 312,302 shares of the company’s stock valued at $20,736,000 after purchasing an additional 32,828 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Perrigo by 5.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 13,686 shares of the company’s stock valued at $1,034,000 after purchasing an additional 736 shares in the last quarter. CIBC Asset Management Inc boosted its stake in shares of Perrigo by 2.4% in the 2nd quarter. CIBC Asset Management Inc now owns 9,685 shares of the company’s stock valued at $731,000 after purchasing an additional 225 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Perrigo by 1,046.2% in the 2nd quarter. Bessemer Group Inc. now owns 2,235 shares of the company’s stock valued at $169,000 after purchasing an additional 2,040 shares in the last quarter. Finally, NJ State Employees Deferred Compensation Plan acquired a new stake in shares of Perrigo in the 2nd quarter valued at approximately $227,000. Hedge funds and other institutional investors own 85.53% of the company’s stock.
WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/05/perrigo-prgo-given-a-107-00-price-target-at-cantor-fitzgerald.html.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.